HealthMore in Health→
Revolution Medicines Signals a New Phase for an Experimental Pancreatic Cancer Drug
Key Takeaways
- Revolution Medicines says it has started shipping an experimental pancreatic cancer drug.
- CEO Mark Goldsmith said an FDA submission is expected soon.
- The update marks a shift from development narrative to regulatory preparation.
- The available materials do not include the supporting clinical data or approval timeline.
DE
DT Editorial Team··via statnews.com